Tumor Necrosis Factor-alpha (TNF-alpha)

Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory cytokine involved in immune signaling and cell death regulation, studied alongside IL-6 as a candidate blood marker of inflammaging. The claim: elevated circulating TNF-alpha independently predicts mortality in older adults, though the evidence shows the relationship is less consistent than for IL-6 and appears to differ meaningfully by sex and by extreme age.

A prospective study of 333 relatively healthy 80-year-olds followed for 6 years (133 deaths) found TNF-alpha was associated with mortality in men but not in women, while low-grade IL-6 elevation predicted mortality strongly in both sexes; adding a TNF-alpha-by-sex interaction term increased the hazard ratio for TNF-alpha nearly ninefold, an effect explained almost entirely by excess risk concentrated in men, and TNF-alpha explained only 7% of the variance in IL-6, indicating the two cytokines act through largely independent pathways [1]. In a different population at the extreme of aging, a study of 126 centenarians followed 5 years (only 9 survivors) found elevated TNF-alpha was associated with mortality in both men and women (hazard ratio 1.34 per standard deviation of 2.81 pg/mL, 95% CI 1.12-1.60, p=0.001), while IL-6 and IL-8 did not significantly predict survival once TNF-alpha was accounted for, and CRP lost significance when TNF-alpha was included in the model [2]. This reversal, TNF-alpha dominant in centenarians but IL-6 dominant in 80-year-olds, illustrates that the relative importance of specific inflammatory markers can shift at extreme ages. In the Health ABC cohort, elevated TNF-alpha carried a hazard ratio of 1.82 for cancer death, the strongest of the three markers measured (IL-6 1.63, CRP 1.64) [3].

How to measure it: serum or plasma immunoassay, ELISA or multiplex, reported in picograms per milliliter, from a standard blood draw [5]. Like IL-6, TNF-alpha shows meaningful assay-to-assay variability and can be transiently elevated by acute infection or inflammatory flares unrelated to baseline chronic inflammaging status.

How to intervene on it: weight loss, aerobic exercise, and anti-inflammatory dietary patterns show modest TNF-alpha-lowering effects in small trials; TNF-alpha inhibitor biologic drugs (e.g., etanercept, adalimumab) are approved for autoimmune diseases like rheumatoid arthritis but are not established longevity interventions in the general population and carry significant infection and immunosuppression risks that outweigh any theoretical benefit for otherwise healthy people.

Critics point to the sex-specific and age-specific inconsistency in TNF-alpha's mortality association, significant in men but not women at age 80, but significant in both sexes among centenarians, as evidence the marker's clinical interpretation is more complicated and population-dependent than for IL-6 [1][2], limiting its standalone usefulness as a general biomarker, a caution echoed in mechanistic reviews of TNF-alpha signaling in cellular senescence [4].

Bryan Johnson's Blueprint protocol includes TNF-alpha within its broader inflammatory panel tracking, an n=1 self-report [6].

The plain takeaway: TNF-alpha is a biologically important inflammatory cytokine with real but inconsistent links to mortality risk that vary meaningfully by sex and age group, making it best interpreted as part of a broader inflammatory panel alongside IL-6 and CRP rather than relied upon alone.